Tag: GLIX1
-
BioLineRx Wins USPTO Allowance for GLIX1 Cancer Therapy Patent
BioLineRx Announces USPTO Notice of Allowance for GLIX1 Patent BioLineRx has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent covering the company’s GLIX1 program. This milestone strengthens the intellectual property framework around GLIX1, a molecule aimed at treating a broad range of cancers.…
-
BioLineRx GLIX1 Patent Receipt: USPTO Notice of Allowance Expands Cancer Treatment Reach
BioLineRx Secures USPTO Notice of Allowance for GLIX1 Patent BioLineRx announced a pivotal milestone: the U.S. Patent and Trademark Office has issued a Notice of Allowance for the GLIX1 patent, covering its use in treating a broad spectrum of cancers. This development marks a significant step in protecting the company’s GLIX1-based therapeutic approach as it…
-
BioLineRx Wins USPTO Notice of Allowance for GLIX1 Cancer Therapy Patent Across Most Cancers
Overview: A Major Step Forward for GLIX1 BioLineRx announced a significant milestone in its cancer therapy program with a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its key patent covering GLIX1. This development marks an important expansion of protection for GLIX1 as a potential treatment for a broad range…